[Changchun Hi-Tech responds to Zhejiang growth hormone gathering rumors: the document has not yet been formally released. Other provinces can basically achieve price-for-volume]. FYF, June 8, yesterday, Changchun high-tech stock prices fell to the limit. On the news, a screenshot of a document entitled "notice on submitting procurement data related to the range of varieties of the fourth batch of drugs purchased by public medical institutions in Zhejiang Province" was circulated online, signed on May 31, 2023. The attachment list includes life growth hormone (recombinant human growth hormone). For the above collection news, on June 8, Changchun high-tech told reporters that the company has recently paid attention to the related news of Zhejiang collection, which is spread online. According to the content of the online document, it now belongs to the reporting stage of medical institutions. At present, the relevant collection policy documents in Zhejiang have not yet been formally issued, and the follow-up company will actively follow the policy changes, fully sum up the early experience, and reasonably formulate and optimize the response plan. Changchun Hi-Tech said that in the past, provinces that have implemented collection can basically achieve the goal of exchanging price for quantity, and have no serious impact on the company's performance (thepaper.cn).